摘要
驱动突变(driver mutation)的发现从某种意义上改变了人类对恶性肿瘤的认识,这在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表现尤为明显。以往对NSCLC的分型仅以组织病理学为基础,现在则加入了以分子改变为基础的分子分型。鉴于表皮生长因子受体(epidermal growth factor receptor,EGFR)、间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)、肝细胞生长因子受体(hepatocyte growth factor receptor,HGFR或MET)等相应基因肺癌驱动突变的发现及逐步深入的研究,以这些基因为靶点的分子靶向药物已经或将在不久的未来使相当数量的患者获益。目前临床获益于靶向相应驱动突变药物的人群绝大多数为肺腺癌患者,然而肺鳞癌亦有较为特征性的驱动突变,对鳞癌驱动突变的深入研究,必将促进该病种个体化医疗的发展,加速其治疗模式的转变。在此将对目前肺鳞癌常见的驱动突变做一综述。
Our knowledge of malignant tumors has been changed profoundly thanks to the discovery of driver mutations,especially in the field of non-small cell lung cancer（NSCLC）.In the past,histopathology was the only basis of typing NSCLC,however,molecular classification that depends on molecular alternations has been widely applied nowadays.In the light of reporting and further studying of EGFR,ALK,MET and other driver mutations,agents that target related genes have benefited a number of patients.However,most patients who benefit from the molecular-targeted agents carry adenocarcinomas rather than squamous cell carcinomas,while there are still some relatively unique driver mutations in squamous cell carcinoma.There is no doubt that the individualized medicine would be promoted and transformed along with the further study of driver mutations in the squamous cell carcinoma of the lung.In this review,some essential driver mutations,mainly focus on their potential clinical significance in the squamous cell carcinoma of the lung,will be discussed.
出处
《现代肿瘤医学》
CAS
2015年第14期2077-2081,共5页
Journal of Modern Oncology
基金
江苏省卫生科研项目(编号:H201235)
南京市医学重点科技发展项目(编号:2KX12012)
关键词
肺鳞癌
驱动突变
个体化医疗
squamous cell carcinoma of the lung
driver mutation
individualized medicine
